Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03877796 · ClinicalTrials.gov registry record
Clinical Pre-screening Protocol for Ovarian Cancer
A clinical trial of Ovarian Cancer, sponsored by Allarity Therapeutics.
- Recruiting
- Registry status
- 60
- Enrollment target
- 5
- Study locations
NCT03877796: Recruiting study of Ovarian Cancer, sponsored by Allarity Therapeutics.
NCT03877796 is a study of Ovarian Cancer that is actively recruiting participants, run by Allarity Therapeutics. The registered enrollment target is 60 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (92% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03877796, a study of Ovarian Cancer, is actively recruiting participants, sponsored by Allarity Therapeutics.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 5
- Study locations
Study Summary
The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.
Primary Outcome
based on FFPE ovarian cancer tissue
Conditions Studied
Interventions
- DEVICE Drug Response Predictor® (DRP)
Study Locations (5)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Oklahoma
- OU Health Stephenson Cancer Center - Oklahoma City
Washington
- Swedish Center for Research and Innovation - Seattle
Scotland
- Beatson West of Scotland Cancer Centre - Glasgow
Other
- Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2019-04-11 |
| Est. Completion | 2026-12 |
What NCT03877796 shows while recruiting
NCT03877796 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Drug Response Predictor® (DRP) is the first listed.
NCT03877796 lists 5 locations in 5 states (Massachusetts, Oklahoma, Washington).
Frequently Asked Questions
What is clinical trial NCT03877796 about?
NCT03877796 is a clinical study titled "Clinical Pre-screening Protocol for Ovarian Cancer". The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity The...
What is the current status of trial NCT03877796?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2019-04-11. Estimated completion is 2026-12.
What conditions does trial NCT03877796 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT03877796?
The interventions under investigation include: Drug Response Predictor® (DRP) (DEVICE).
Who is sponsoring clinical trial NCT03877796?
This trial is sponsored by Allarity Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03877796 being conducted?
This trial has 5 study locations across Massachusetts, Oklahoma, Washington, Scotland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03877796's enrollment target sits among peer trials
60 193rd of 322 higher than 123 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
RECRUITING
-
The Better, Harder, Faster, Stronger Study
RECRUITING
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI